ClinicalTrials.gg
WithdrawnNCT07706868Updated Jul 16, 2026

An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)

A Phase 4 interventional study of Anakinra (Kineret®) in Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still's Disease (AOSD), sponsored by Swedish Orphan Biovitrum. Withdrawn. Open to participants aged 8 Months and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Swedish Orphan Biovitrum · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
8 Months and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD).The study consists of up to four weeks screening, to see if a patient is suitable to the study, 48 weeks of treatment with anakinra and 4 weeks safety follow up after last dose of anakinra. In total 60 patients(expected allocation is 30 SJIA and 30 AOSD), male or female patients, 8 months of age or older with a body weight ≥ 10 kg, will be enrolled to the study.

Read the detailed description

This is a prospective, open-label, multicenter, efficacy and safety study of anakinra in Chinese patients with Still's disease (SJIA and AOSD). The study consists of a 48-Week treatment period with anakinra followed by a 4-Week period to evaluate safety of anakinra after the last dose of IMP. The study is divided into three parts: screening, treatment period, and safety follow-up, and will be performed in China.

The study will recruit a total of 60 patients (expected allocation is 30 SJIA and 30 AOSD).

The patient will enter screening after informed consent is obtained and will undergo screening assessments to confirm eligibility. Duration of the screening period will be kept as short as possible and should not exceed 4 weeks.

Patients will be assigned to study drug after they have met all of the inclusion criteria and none of the exclusion criteria. Patients will receive treatment with anakinra for 48 weeks.

After the last dose of anakinra at Week 48, the safety will continue to be evaluated at a Safety Follow-up visit i.e., at Week 52.

14 visits and 1 telephone contact are scheduled during the study as follows: Screening visit (Visit 0), Day 1 (Baseline visit), Day 4Tel, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48 (last dose of anakinra), and Week 52 (end of study).

All patients included in the study will be carefully monitored by the investigator. Patients can withdraw from the study drug at any time for any reason. If a patient permanently discontinues study drug, at any time during the study prior to week 48, a Study Drug Discontinuation visit should be performed, if possible before standard of care treatment is initiated. If clinically not feasible, the Study Drug Discontinuation visit should be performed as soon as possible.

4 weeks after discontinuation of study drug, a subsequent Safety Follow-up visit will be performed, according to the assessments described for the Week 52 visit, after which the patient will be withdrawn from the study.

02

Conditions studied

  • Systemic Juvenile Idiopathic Arthritis (sJIA)
  • Adult Onset Still's Disease (AOSD)
03

In context

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Lead sponsor

Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. form signed by the patient or a legal guardian representative.
  2. Male or female patients, 8 months of age or older with a body weight ≥ 10 kg.
  3. Diagnosis of Still's disease.
  4. Criteria for diagnosis of Still's disease:

    1. If \< 16 years of age at disease onset, the diagnosis is made according to international league for associations of rheumatology (ILAR) criteria for SJIA.
    2. If ≥ 16 years of age at disease onset, the diagnosis is made according to Yamaguchi criteria for AOSD.
  5. Active disease confirmed by the following three signs and symptoms:

    1. Active arthritis in ≥ 1 joint.
    2. CRP > 30 mg/L.
    3. At least one fever episode attributable to the disease within one week before enrollment.

    Definition of fever: Body temperature ≥ 38.0 °C attributable to the disease

  6. Background treatment with stable dose of ≤ 1 mg/kg/d (Max 60 mg/d) of oral prednisolone or equivalent for at least 3 days prior to enrollment is permitted.
  7. If currently on methotrexate (MTX) treatment, the dose must be stable for at least 4 weeks prior to enrollment. Maximum dose allowed is 20 mg/m2/week. If the patient discontinued MTX prior to enrollment, the discontinuation is required to be at least 4 weeks prior to enrollment.
  8. Female patients of and male patient with female partner of childbearing potential must use an effective method of during the study (abstinence being a possible option). A negative pregnancy test prior to enrollment is also required.
  9. In case of use of oral contraception, women should have been stable on the same brand (or generic equivalent) for a minimum of 3 months before taking study treatment.
  10. Negative tuberculosis screening confirmed at the Screening visit by the Mantoux Tuberculin skin test (TST) using purified protein derivative (PPD), or by Interferon-Gamma-Release Assays (IGRAs) e.g., QuantiFERON® TB Gold Plus (QFT-Plus) or T¬Spot-® (TB Test) within 8 weeks prior to enrollment. Negative results must be complemented by the medical history, physical examination, and Chest X-Ray. Patients presenting positive TST or IGRA, with or without active or clinical suspicion of latent tuberculosis, are not eligible to enter the study.

Previously vaccinated for Tuberculosis patients: IGRA positive patients are not eligible to enter the Study; TST positive patients with an induration of 15 mm and more are also not eligible to enter the study, TST positive patients (with an induration less than 15 mm) are also not eligible to enter the study, unless an IGRA test is subsequently performed and provides a negative result.

Exclusion criteria

Exclusion Criteria:

  1. Previous enrollment to this study
  2. Participation in another clinical interventional study 30 days prior to enrollment.
  3. Treatment with an drug within 5 half-lives prior to enrollment.
  4. Previous or current treatment with anakinra, or any other IL-1 inhibitor, except for canakinumab. Previous treatment with canakinumab is allowed if canakinumab was discontinued for reasons other than lack of efficacy and after a of minimum 130 days (Refer to Exclusion Criteria 5). Patients who have discontinued canakinumab because of insufficient effect, disease or toxicities are not allowed to be enrolled in the study.
  5. Use of the following therapies prior to enrollment:

    • Narcotic analgesics within 24 hours prior to enrollment.
    • Dapsone within 1 week prior to enrollment or etanercept within 2 weeks prior to enrollment.
    • Intraarticular, intramuscular, or intravenous administration of within 72h (3 days) prior to enrollment, or intravenous immunoglobulin within 4 weeks prior to enrollment.
    • Leflunomide, infliximab or adalimumab within 8 weeks prior to enrollment.
    • Thalidomide within 72h (3 days) prior to enrollment, cyclosporine within 5 weeks prior to enrollment, tacrolimus hydrate within 2 weeks prior to enrollment, mycophenolate mofetil within 1 week prior to enrollment, 6-mercaptopurine within 48h (2 days) prior to enrollment, azathioprine within 72h (3 days) prior to enrollment, cyclophosphamide within 96h (4 days) prior to enrollment, chlorambucil within 48h (2 days) prior to enrollment, Janus kinase (JAK) inhibitors within 5 half-lives prior to enrollment, or any other within 12 weeks prior to enrollment.
    • Tocilizumab within 4 weeks prior to enrollment or any other immunomodulatory medication within 5 half-lives prior to enrollment.
    • Rituximab within 26 weeks prior to enrollment.
    • Canakinumab within 130 days prior to enrollment.
  6. within 4 weeks prior to enrollment.
  7. Known presence or suspicion of active, chronic or recurrent bacterial, fungal or viral infections, including but not limited to tuberculosis, (HIV) infection, coronavirus disease (Covid-19) infection, or C infection at baseline.
  8. Clinical evidence of liver disease or liver injury as indicated by presence of abnormal liver tests:

    1. (AST) or alanine aminotransferase (ALT) > 5 x (ULN), or
    2. AST or ALT > 3 x ULN and elevated > 2 x ULN.
  9. Presence of severe chronic kidney disease (CKD) stages 4 and 5 (estimated \< 30 mL/min/1.73m2).
  10. Presence of neutropenia (ANC \< 1.5 x 109/L).
  11. Presence of thrombocytopenia ( count \< 100 x 109/L).
  12. Presence or suspicion of macrophage activation syndrome (MAS) at baseline.
  13. A diagnosis of macrophage activation syndrome (MAS) within the last 2 months prior to enrollment.
  14. History of within 5 years prior to enrollment. Exceptions are basal cell skin cancer, carcinoma-in-situ of the cervix, or low-risk prostate cancer after curative therapy.
  15. Known to E. Coli-derived proteins, or any components of anakinra.
  16. Pregnant or lactating women.
  17. Foreseeable inability to cooperate with given instructions or study procedures.
  18. Presence of any medical, psychological condition, or laboratory result that in the opinion of the investigator can interfere with the patient's ability to comply with the protocol requirements, or make the patient not appropriate for inclusion to the study and treatment with IMP.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Anakinra

    Anakinra, once daily s.c. injection, starting dose of 100 mg/day for patients with body weight ≥ 50 kg and 1-2 mg/kg/day for patients with body weight \< 50 kg. Pediatric and adult patients weighing ≥ 50kg will receive 100 mg anakinra per day by subcutaneous injection. Pediatric and adult patients weighing \< 50 kg should be dosed by body weight with a starting dose of anakinra of 1 to 2 mg/kg/day (with a max of 100 mg/day). If patients receiving 1 mg/kg/d are not responding at Week 1, the dose will be escalated to 2 mg/kg/day. If at the appreciation of the investigator, a patient \< 16 years old with a body weight below 50 kg, is not responding sufficiently to anakinra treatment at Week 4 visit, the dose will be adjusted according to actual body weight (rounded to the nearest kg) and will be increased up to 4 mg/kg/day with a max of 200 mg/day or the continuation of anakinra will be considered by the investigator.

    Drug: Anakinra (Kineret®)

Interventions

06

What researchers measure

Primary outcomes

  1. ACR30 response at Week 4 with absence of fever attributable to the disease during the 7 days preceding Week 4 visit.

    Definition of American College of Rheumatology (ACR) 30 response in SJIA and AOSD patients: An improvement of ≥ 30% from baseline to Week 4 visit, in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by \> 30%. 1. Physician global assessment of disease activity (visual analogue scale \[VAS\]). 2. Patient/parent global assessment of overall well-being (VAS). 3. Number of joints with active arthritis. 4. Number of joints with limitation of motion. 5. Assessment of physical function (Child health assessment questionnaire \[CHAQ\]/ Stanford health assessment questionnaire \[SHAQ\]). 6. CRP (mg/L). Definition of fever: Body temperature ≥ 38.0 °C attributable to the disease. Definition of active arthritis: Joint with swelling. In absence of swelling, limitation of range of motion accompanied by either pain on motion or tenderness not due to deformity.

    Time frame: Up to 48 weeks.

Secondary outcomes

  1. Absence of fever during the 7 days preceding week 4.

    Time frame: Up to week 48.

  2. Absence of rash during the 7 days preceding Week 4.

    Time frame: Up to week 48.

  3. ACR50, ACR70, and ACR90 response with absence of fever during the 7 days preceding Week 4.

    Time frame: Up to week 48.

  4. Absence of fever during the 7 days preceding each visit.

    Time frame: Up to week 48.

  5. Absence of rash during the 7 days preceding each visit.

    Time frame: Up to week 48.

  6. ACR30 response with absence of fever during the 7 days preceding each visit.

    Definition of ACR30 response in SJIA and AOSD patients: An improvement of ≥ 30%, in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by \> 30%, and no intermittent fever attributable to the disease during the preceding 7 days.

    Time frame: Up to week 48.

  7. ACR50 response with absence of fever during the 7 days preceding each visit.

    Definition of ACR50 response in SJIA and AOSD patients: An improvement of ≥ 50%, in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by \> 30%, and no intermittent fever attributable to the disease during the preceding 7 days.

    Time frame: Up to week 48.

  8. ACR70 response with absence of fever during the 7 days preceding each visit.

    Definition of ACR70 response in SJIA and AOSD patients: An improvement of ≥ 70% in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by \> 30%, and no intermittent fever attributable to the disease during the preceding 7 days.

    Time frame: Up to week 48.

  9. ACR90 response with absence of fever during the 7 days preceding each visit.

    Definition of ACR90 response in SJIA and AOSD patients: An improvement of ≥ 90% in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by \> 30%, and no intermittent fever attributable to the disease during the preceding 7 days.

    Time frame: Up to week 48.

  10. Change from baseline in physician global assessment of disease activity (VAS).

    Time frame: Up to week 48.

  11. Change from baseline in patient/parent global assessment of overall well-being (VAS).

    Time frame: Up to week 48.

  12. Change from baseline in C-reactive protein (CRP) concentrations.

    CRP levels (measured in mg/L) will be determined in serum.

    Time frame: Up to week 48.

  13. Change from baseline in ferritin concentrations.

    Ferritin levels (measured in ng/ml) will be determined in serum.

    Time frame: Up to week 48.

  14. Change from white blood cell counts.

    White blood cell counts (measured in cells per μL) will be determined in serum.

    Time frame: Up to week 48.

  15. Occurrence of inactive disease

    Proportion of patients who reach inactive disease at Week 8 and at the following respective visits up to Week 48.

    Time frame: Up to week 48.

  16. Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), deaths, and AEs leading to study drug discontinuation

    An AE is any untoward medical occurrence in a study patient to whom a medicinal product is administered, and which does not necessarily have a causal relationship with this treatment. AEs include abnormal test findings, clinically significant signs and symptoms, changes in physical examination findings, progression or worsening of underlying disease. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.

    Time frame: Up to week 52.

  17. Changes over time in blood pressure

    Blood pressure (mmHg) change of each patient are evaluated over time.

    Time frame: Up to week 48.

  18. Changes over time in heart rate

    Heart rate (beats per minute) change of each patient are evaluated over time.

    Time frame: Up to week 48.

  19. Changes over time in body temperature

    Body temperature (Celsius degrees) change of each patient are evaluated over time.

    Time frame: Up to week 48.

  20. Changes over time in body weight

    Body weight (kilograms) for all patients are evaluated over time.

    Time frame: Up to week 48.

  21. Changes over time in height

    Height (centimeters) are evaluated over time for pediatric patients

    Time frame: Up to week 48.

  22. Changes over time in Laboratory safety assessment

    Time frame: Up to week 48.

  23. Number of patients with abnormal laboratory values

    Time frame: Up to week 48.

  24. Evaluation of the pharmacokinetic of anakinra in patients with Still's disease.

    Anakinra serum concentration at Baseline, Week 2 and Week 4 visits.

    Time frame: Up to 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Sep 2028, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 16, 2026
StartEst.
Sep 1, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07706868
Collaborators
Tigermed Consulting Co., Ltd
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Sep 1, 2025 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jul 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein

Start the discussion